AbbVie Stock News

Blue chip stocks dominate the list of hedge funds' most popular equity investments.

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapy FL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western...

AbbVie is a Dividend King that's poised for future growth. Enbridge offers an ultra-high dividend yield and is expanding into more areas of the energy sector.

Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.

AbbVie enables retirees to profit from both its dividend payouts and its promising growth opportunities. Verizon has a safe high-yielding dividend, which the company has been growing steadily in recent years.

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.

Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day.

24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.